Description

Danaher Raises Guidance As Mid-Teens Bioprocessing Orders Signal A Rebound!

Danaher Corporation reported second quarter 2026 results that reflected a combination of better-than-expected revenue, earnings, and cash flow, against a backdrop of mixed end-market conditions. Total sales for the quarter reached $6.3 billion with core revenue growth of 3% year-over-year, accelerating to 4.5% when excluding respiratory testing revenue. The company acknowledged shipment timing challenges in the Biotechnology segment, particularly within bioprocessing, which caused a delay in revenues but did not alter underlying demand trends as evidenced by robust mid-teens order growth in equipment and consumables. Management noted these shipment shifts primarily related to a few large commercial customers’ production scheduling and site readiness, resulting in an estimated $50-60 million revenue impact in Q2 and deferral of approximately $100 million into 2027. Life Sciences and Diagnostics segments showed healthier trends, with Life Sciences core revenue rising 5.